News

Under the agreement, Depomed has granted Watson a co-exclusive right to promote ProQuin XR for the urology and long-term care specialties in the US and its possessions, including

Arius said that it expects to file an IND application and begin human clinical trials in 2008. The biotechnology company is developing the compound for the treatment of

The first part of the trial is a single arm, open-label dose titration to evaluate the effective individual dose for significant pain relief with fentanyl Taifun in the

Netherlands-based Qiagen said that preliminary tabulations suggest that the number of shares tendered constitute well over 90% of Digene’s stock, meaning that the company can go on to

Veralipride is marketed under the trade names of Agreal or Agradil in Belgium, France, Italy, Luxembourg and Portugal by Sanofi-Aventis. The EMEA’s Committee for Medicinal Products for Human

The drug, ANX-201, combined at fixed ratios with nucleoside and nucleotide reverse transcriptase inhibitors (N(t)RTIs) including zidovudine, tenofovir, abacavir, lamivudine, emtricitabine and stavudine resulted in synergistic to additive

A decision by the FDA on the label revision is expected by the end of March 2008. “We are pleased to report the FDA acceptance of this filing

The open offer for Matrix could be a first step in delisting the company from the stock markets, which would release the company from its regulatory obligations, the

The study will be conducted within a network of approximately 25 sites under the direction of the National Cancer Institute funded Community Clinical Oncology Program, according to the